Literature DB >> 29953728

CHIP promotes autophagy-mediated degradation of aggregating mutant p53 in hypoxic conditions.

Meenu Maan1, Uttam Pati1.   

Abstract

Tumor suppressor protein p53 aggregates in the hypoxic core of solid tumors. C terminus of Hsc70-interacting protein (CHIP) displays chaperone as well as E3 ligase activities in both stabilizing and degrading wild-type and mutant p53. In this study, we have discovered that CHIP selectively degrades aggregating mutant p53 under both normal and hypoxic conditions. Silencing of CHIP alleviates degradation of aggregating mutant p53 in both normoxia and hypoxia, but has no significant effect on the level of nonaggregating mutant p53. Although both U-box and TPR domains of CHIP are responsible for p53 degradation, the U-box domain selectively binds to aggregating mutant p53, whereas the TPR domain interacts with nonaggregating mutant p53. The degradation of mutant p53 by CHIP is shown to be via autophagy through K63-linked polyubiquitination. Both in normoxia and under physiological hypoxia, the level of aggregating mutant p53 in the presence of CHIP was reduced threefold, whereas under serum starvation, it was reduced fivefold. Interestingly, both wild-type and mutant p53 interact with and stabilize CHIP at the post-translational level, suggesting a chaperone synergy between p53 and CHIP. This finding may have strong therapeutic significance via selective degradation of oncogenic mutant p53 in regressing hypoxic tumors.
© 2018 Federation of European Biochemical Societies.

Entities:  

Keywords:  zzm321990CHIPzzm321990; aggregating mutant; autophagy; p53; ubiquitination

Mesh:

Substances:

Year:  2018        PMID: 29953728     DOI: 10.1111/febs.14602

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  13 in total

1.  The impacts of ubiquilin 1 (UBQLN1) knockdown on cells viability, proliferation, and apoptosis are mediated by p53 in A549 lung cancer cells.

Authors:  Xinghua Zhang; Yunshu Su; Huiqing Lin; Xiaoli Yao
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

Review 2.  Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

Authors:  Liz J Hernández Borrero; Wafik S El-Deiry
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-04-29       Impact factor: 11.414

3.  The complexity of p53-mediated metabolic regulation in tumor suppression.

Authors:  Yanqing Liu; Wei Gu
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 17.012

Review 4.  Regulators of Oncogenic Mutant TP53 Gain of Function.

Authors:  Satomi Yamamoto; Tomoo Iwakuma
Journal:  Cancers (Basel)       Date:  2018-12-20       Impact factor: 6.639

Review 5.  F-Box Proteins and Cancer.

Authors:  Kanae Yumimoto; Yuhei Yamauchi; Keiichi I Nakayama
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

6.  DpdtC-Induced EMT Inhibition in MGC-803 Cells Was Partly through Ferritinophagy-Mediated ROS/p53 Pathway.

Authors:  Jiankang Feng; Cuiping Li; Ruifang Xu; Yongli Li; Qi Hou; Rui Feng; Senye Wang; Lei Zhang; Changzheng Li
Journal:  Oxid Med Cell Longev       Date:  2020-03-12       Impact factor: 6.543

7.  Autophagy augments the self-renewal of lung cancer stem cells by the degradation of ubiquitinated p53.

Authors:  Jianyu Wang; Doudou Liu; Zhiwei Sun; Ting Ye; Jingyuan Li; Bin Zeng; Qiting Zhao; H Rosie Xing
Journal:  Cell Death Dis       Date:  2021-01-19       Impact factor: 8.469

Review 8.  Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.

Authors:  Eduardo Alvarado-Ortiz; Karen Griselda de la Cruz-López; Jared Becerril-Rico; Miguel Angel Sarabia-Sánchez; Elizabeth Ortiz-Sánchez; Alejandro García-Carrancá
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 9.  The Multifaceted Role of CMA in Glioma: Enemy or Ally?

Authors:  Alessia Lo Dico; Cristina Martelli; Cecilia Diceglie; Luisa Ottobrini
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

10.  Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells.

Authors:  Eduardo García-Garrido; Marco Cordani; Álvaro Somoza
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.